Boehringer, Forma Strike Discovery Deal In Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.